<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39264730</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-7448</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Immunotherapy</Title><ISOAbbreviation>Immunotherapy</ISOAbbreviation></Journal><ArticleTitle>A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.</ArticleTitle><Pagination><StartPage>759</StartPage><EndPage>774</EndPage><MedlinePgn>759-774</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/1750743X.2024.2359359</ELocationID><Abstract><AbstractText><b>Aim:</b> This first-in-human study evaluated safety and efficacy of CD40 agonist MEDI5083 with durvalumab in patients with advanced solid tumors.<b>Methods:</b> Patients received MEDI5083 (3-7.5 mg subcutaneously every 2 weeks × 4 doses) and durvalumab (1500 mg every 4 weeks) either sequentially (N = 29) or concurrently (N = 9). Primary end point was safety; secondary end points included efficacy.<b>Results:</b> Thirty-eight patients received treatment. Most common adverse events (AEs) were injection-site reaction (ISR; sequential: 86%; concurrent: 100%), fatigue (41%; 33%), nausea (20.7%; 55.6%) and decreased appetite (24.1%; 33.3%). Nine patients had MEDI5083-related grade ≥3 AEs with ISR being the most common. Two patients experienced dose limiting toxicities (ISR). One death occurred due to a MEDI5083-related AE. MEDI5083 maximum tolerated dose was 5 mg. Objective response rate was 2.8% (1 partial response and 11 stable disease).<b>Conclusion:</b> MEDI5083 toxicity profile limits its further development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Ben</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-9124-354X</Identifier><AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, Melbourne, 8006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voskoboynik</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nucleus Network, Melbourne, 3004, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash University, Melbourne, 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendell</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN 37203, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hackensack University Medical Center, Hackensack, NJ 07601, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemech</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Scientia Clinical Research, Randwick, 2031, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of New South Wales, Sydney, 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Daphne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Monash University, Melbourne, 3004, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash Medical Centre, Clayton, 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frentzas</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Monash University, Melbourne, 3004, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Monash Medical Centre, Clayton, 3800, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrido-Laguna</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Huntsman Cancer Institute, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Standifer</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, R&amp;D, AstraZeneca, South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fujun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Oncology Biometrics, AstraZeneca, Gaithersburg, MD 20878,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferte</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AstraZeneca, Gaithersburg, MD 20878,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AstraZeneca, Gaithersburg, MD 20878,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Mayukh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AstraZeneca, Gaithersburg, MD 20878,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carneiro</LastName><ForeName>Benedito A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI 02903,USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>AstraZeneca United States</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunotherapy</MedlineTA><NlmUniqueID>101485158</NlmUniqueID><ISSNLinking>1750-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>28X28X9OKV</RegistryNumber><NameOfSubstance UI="C000613593">durvalumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019013">CD40 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019013" MajorTopicYN="Y">CD40 Antigens</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020714" MajorTopicYN="N">Maximum Tolerated Dose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>MEDI5083 is a molecule that was designed as a potential anticancer medication. Once inside the body, MEDI5083 connects to specific proteins found on the surface of immune cells and cancer cells. It can boost the immune system of the body in multiple ways to help kill cancer cells. In this clinical study, 38 patients with various types of cancers (bladder, breast, colon, head and neck, kidney, lung, and pancreas) were treated with MEDI5083 together with another anticancer medicine called durvalumab. MEDI5083 was given to patients as an injection under the skin once every 2 weeks. Durvalumab was given to patients as an infusion once every 4 weeks. The study monitored whether treatment caused unwanted side effects and whether MEDI5083 was able to shrink the size of tumors.A total of 34 of 38 patients who received treatment experienced unwanted reactions at the site of MEDI5083 treatment injection. These symptoms were long lasting and did not go away with an applied steroid treatment. A total of 5 of 38 patients experienced extreme tiredness and 4 of 38 patients experienced fever. Of 38 patients enrolled, 6 discontinued treatment because of a MEDI5083-related side effect. Only one patient had a decrease in the size of their cancer mass with treatment. Because of safety concerns, this study was not completed. The injectable form of MEDI5083 is not being further tested in patients with cancer.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD40</Keyword><Keyword MajorTopicYN="N">CD40L</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">fusion protein</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>BT received grants and personal fees from Amgen, grants and personal fees from AstraZeneca, grants from Astellas, grants and personal fees from BMS, grants and personal fees from Janssen, grants and personal fees from Pfizer, grants and personal fees from MSD, grants and personal fees from Ipsen, personal fees from IQVIA, personal fees from Sanofi, personal fees from Tolmar, personal fees from Novartis and grants and personal fees from Bayer outside the submitted work. MV has received personal fees from AstraZeneca and MSD outside the submitted work. Research funding (institutional) from AstraZeneca, MSD, Alpine Immune Sciences, Virocure, Hinova Pharmaceuticals, Atridia/Hengrui, Antengene and Beigene. JB has received research funding (institutional) from: Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Koltan, SynDevRex, Forty Seven, AbbVie, Array, Onyx, Sanofi, Takeda, Eisai, Celldex, Agios, Cytomx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Evelo, FORMA, Merus, Jacobio, Effector, Novocare, Arrys, Tracon, Sierra, Innate, Arch Oncology, Prelude Oncology, Unum Therapeutics, Vyriad, Harpoon, ADC, Amgen, Pfizer, Millennium, Imclone, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Seattle Genetics, TempestTx, Shattuck Labs, Synthorx, Inc., Revolution Medicines, Inc., Bicycle Therapeutics, Zymeworks, Relay Therapeutics, Scholar Rock, NGM Biopharma, Stemcentrx, Beigene, CALGB, Cyteir Therapeutics, Foundation Bio, Innate Pharma, Morphotex, OncXerna, NuMab, AtlasMedx, Treadwell Therapeutics, IGM Biosciences, Mabspace, Hutchinson MediPharma, REPARE Therapeutics, NeoImmune Tech, Regeneron and PureTech Health; Consulting/advisory role (institutional) for: Gilead, Genentech/Roche, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, ARMO, Ipsen, Merrimack, Oncogenex, FORMA, Arch Oncology, Prelude Therapeutics, Phoenix Bio, Cyteir, Molecular Partners, Innate, Torque, Tizona, Janssen, Tolero, Amgen, Seattle Genetics, Moderna Therapeutics, Tanabe Research Laboratories, Beigene, Continuum Clinical, Agios, Bicycle Therapeutics, Relay Therapeutics, Evelo, Pfizer, Samsung Bioepios and Fusion Therapeutics; Travel and food accommodations from: Gilead, Genentech/Roche, BMS, Lilly, Merck, MedImmune, Celgene, Taiho, Novartis, OncoMed, BI, ARMO, Ipsen, Oncogenex and FORMA. MG has received research funding (institutional) from: BMS, Merck, Incyte, NextCure, Pfizer, Roche/Genentech, Boehringer Ingelheim, GSB Pharmaceuticals, Moderna Therapeutics, Eisai, Silenseed, Seattle Genetics, Regeneron, Sanofi, Johnson &amp; Johnson, MedImmune, Checkpoint Therapeutics, Acerta Pharmaceuticals, Arcus Biosciences, Array Biopharma, Bayer, Celgene, Compass Therapeutics, Constellation Pharmaceuticals, Cyteir, EMD Serano, Fate Therapeutics, GlaxoSmithKline, Infinity Pharmaceuticals, Pharmacyclics, Synlogic, Tesaro, Vedanta Biosciences, Millennium, Memorial Sloan-Kettering Cancer Center, Rapa Therapeutics, Turning Point Therapeutics, VelosBio, Vincerx Pharmaceuticals, Verstem, Hackensack Meridian Health, Erasca, Inc., Imugene, Incyte Biosciences International, iTeos Therapeutics, KSQ Therapeutics, Nimbus Saturn, Inc.,Georgetown University, Janssen, Mirati Therapeutics, Adlai Nortye, Bellicum Pharmaceuticals, Cullinan MICA Corporation and Daiichi Sankyo Company. CL has nothing to disclose. DD has received Institutional research support: Beigene, Pfizer, EpimAb Biotherapeutics, Harbour BioMed, Maxinovel, PharmAbcine, Olema, Roche, MSD and Bristol-Myers Squibb. SF Honoraria/expenses: Amgen; Consulting/Advisory Boards: Akeso BioPharma. IG-L Institutional research support: Revolution Medicine, BridgeBio, Pfizer, Bayer, MedImmune, Sumitomo, Repare Therapeutics, Amgen, Novartis, Lilly, BMS, RedHill, Incyte, OncoMed. Honoraria for DSMC: SOTIO. Consulting: Jazz Pharmaceuticals, Kanaph, Sumitomo, OncXerna. NS was an employee of AstraZeneca and may own stock or stock options. FW is an employee of AstraZeneca and may own stock or stock options. CF was an employee of AstraZeneca at the time the study was conducted. MD is an employee of AstraZeneca and may own stock or stock options. BAC Institutional research support: AstraZeneca, AbbVie, Bayer, Pfizer, Daiichi Sankyo, Dragonfly Therapeutics, Actuate Therapeutics, Astellas, Repare Therapeutics. Ad boards: Foundation Medicine, Seagen. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>12</Day><Hour>19</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>12</Day><Hour>12</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39264730</ArticleId><ArticleId IdType="pmc">PMC11421296</ArticleId><ArticleId IdType="doi">10.1080/1750743X.2024.2359359</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Elgueta R, Benson MJ, de Vries VC, et al. . Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–172. doi:10.1111/j.1600-065X.2009.00782.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2009.00782.x</ArticleId><ArticleId IdType="pmc">PMC3826168</ArticleId><ArticleId IdType="pubmed">19426221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chand Dakal T, Dhabhai B, Agarwal D, et al. . Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders. Immunobiology. 2020;225:151899. doi:10.1016/j.imbio.2019.151899</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2019.151899</ArticleId><ArticleId IdType="pubmed">31899051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett SR, Carbone FR, Karamalis F, et al. . Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478–480. doi:10.1038/30996</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/30996</ArticleId><ArticleId IdType="pubmed">9624004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474–478. doi:10.1038/30989</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/30989</ArticleId><ArticleId IdType="pubmed">9624003</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenberger SP, Toes RE, van der Voort EI, et al. . T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480–483. doi:10.1038/31002</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31002</ArticleId><ArticleId IdType="pubmed">9624005</ArticleId></ArticleIdList></Reference><Reference><Citation>Caux C, Massacrier C, Vanbervliet B, et al. . Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263–1272. doi:10.1084/jem.180.4.1263</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.180.4.1263</ArticleId><ArticleId IdType="pmc">PMC2191669</ArticleId><ArticleId IdType="pubmed">7523569</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillatreau S. B-cells and their cytokine activities implications in human diseases. Clin Immunol. 2018;186:26–31. doi:10.1016/j.clim.2017.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.07.020</ArticleId><ArticleId IdType="pmc">PMC5844600</ArticleId><ArticleId IdType="pubmed">28736271</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata Y, Matsushita T, Horikawa M, et al. . Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117:530–541. doi:10.1182/blood-2010-07-294249</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-07-294249</ArticleId><ArticleId IdType="pmc">PMC3031478</ArticleId><ArticleId IdType="pubmed">20962324</ArticleId></ArticleIdList></Reference><Reference><Citation>Duddy M, Niino M, Adatia F, et al. . Distinct effector cytokine profiles of memory and naive human B-cell subsets and implication in multiple sclerosis. J Immunol. 2007;178:6092–6099. doi:10.4049/jimmunol.178.10.6092</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.10.6092</ArticleId><ArticleId IdType="pubmed">17475834</ArticleId></ArticleIdList></Reference><Reference><Citation>Altenburg A, Baldus SE, Smola H, et al. . CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol. 1999;162:4140–4147.</Citation><ArticleIdList><ArticleId IdType="pubmed">10201939</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxendale AJ, Dawson CW, Stewart SE, et al. . Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene. 2005;24:7913–7923. doi:10.1038/sj.onc.1208929</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208929</ArticleId><ArticleId IdType="pubmed">16091748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakkarainen T, Hemminki A, Pereboev AV, et al. . CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin Cancer Res. 2003;9:619–624.</Citation><ArticleIdList><ArticleId IdType="pubmed">12576427</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Oord JJ, Maes A, Stas M, et al. . CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol. 1996;149:1953–1961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865371</ArticleId><ArticleId IdType="pubmed">8952530</ArticleId></ArticleIdList></Reference><Reference><Citation>Slobodova Z, Ehrmann J, Krejci V, et al. . Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. Neoplasma. 2011;58:189–197. doi:10.4149/neo_2011_03_189</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/neo_2011_03_189</ArticleId><ArticleId IdType="pubmed">21391734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa K, Miyamoto M, Yoshioka T, et al. . Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis. Cancer. 2008;113:530–541. doi:10.1002/cncr.23618</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.23618</ArticleId><ArticleId IdType="pubmed">18548529</ArticleId></ArticleIdList></Reference><Reference><Citation>Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014;35:9447–9457. doi:10.1007/s13277-014-2407-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-014-2407-x</ArticleId><ArticleId IdType="pmc">PMC4213374</ArticleId><ArticleId IdType="pubmed">25117071</ArticleId></ArticleIdList></Reference><Reference><Citation>Turman S, McGlinchey K, Wang Y, et al. . MEDI5083, a novel CD40L-Fc fusion protein, activates the CD40 pathway on antigen presenting cells and promotes a robust anti-tumor immune response in a B16F10 murine tumor model. Cancer Res. 2019;79:1534. doi:10.1158/1538-7445.Am2019-1534</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.Am2019-1534</ArticleId></ArticleIdList></Reference><Reference><Citation>Long KB, Gladney WL, Tooker GM, et al. . IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 2016;6:400–413. doi:10.1158/2159-8290.CD-15-1032</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-15-1032</ArticleId><ArticleId IdType="pmc">PMC4843521</ArticleId><ArticleId IdType="pubmed">26896096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zippelius A, Schreiner J, Herzig P, et al. . Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015;3:236–244. doi:10.1158/2326-6066.CIR-14-0226</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0226</ArticleId><ArticleId IdType="pubmed">25623164</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart R, Morrow M, Hammond SA, et al. . Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3:1052–1062. doi:10.1158/2326-6066.CIR-14-0191</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0191</ArticleId><ArticleId IdType="pubmed">25943534</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Wang SJ, Yang S, et al. . A Bayesian interval dose-finding design addressing Ockham's razor: mTPI-2. Contemp Clin Trials. 2017;58:23–33. doi:10.1016/j.cct.2017.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2017.04.006</ArticleId><ArticleId IdType="pubmed">28458054</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247. doi:10.1016/j.ejca.2008.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2008.10.026</ArticleId><ArticleId IdType="pubmed">19097774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley RK, Sangro B, Harris W, et al. . Safety, efficacy and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J Clin Oncol. 2021;39:2991–3001. doi:10.1200/JCO.20.03555</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.03555</ArticleId><ArticleId IdType="pmc">PMC8445563</ArticleId><ArticleId IdType="pubmed">34292792</ArticleId></ArticleIdList></Reference><Reference><Citation>Irenaeus SMM, Nielsen D, Ellmark P, et al. . First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int J Cancer. 2019;145:1189–1199. doi:10.1002/ijc.32141</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32141</ArticleId><ArticleId IdType="pubmed">30664811</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonderheide RH, Flaherty KT, Khalil M, et al. . Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876–883. doi:10.1200/JCO.2006.08.3311</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2006.08.3311</ArticleId><ArticleId IdType="pubmed">17327609</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson P, Challis R, Chowdhury F, et al. . Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin Cancer Res. 2015;21:1321–1328. doi:10.1158/1078-0432.CCR-14-2355</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2355</ArticleId><ArticleId IdType="pubmed">25589626</ArticleId></ArticleIdList></Reference><Reference><Citation>Imfinzi® (Durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.</Citation></Reference><Reference><Citation>Choquette D, Bessette L, Brown J, et al. . 
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry [abstract]. Arthritis Rheumatol.
2018;70(Suppl. 9). https://acrabstracts.org/abstract/injection-site-reaction-associated-with-subcutaneous-biologic-agents-and-methotrexate-analysis-from-the-rhumadata-clinical-database-and-registry/</Citation></Reference><Reference><Citation>Beatty GL, Torigian DA, Chiorean EG, et al. . A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013;19:6286–6295. doi:10.1158/1078-0432.CCR-13-1320</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-13-1320</ArticleId><ArticleId IdType="pmc">PMC3834036</ArticleId><ArticleId IdType="pubmed">23983255</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47–58. doi:10.1146/annurev-med-062518-045435</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-062518-045435</ArticleId><ArticleId IdType="pubmed">31412220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajor DL, Mick R, Riese MJ, et al. . Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 2018;7:e1468956. doi:10.1080/2162402X.2018.1468956</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2018.1468956</ArticleId><ArticleId IdType="pmc">PMC6169575</ArticleId><ArticleId IdType="pubmed">30288340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak AK, Cook AM, McDonnell AM, et al. . A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015;26:2483–2490. doi:10.1093/annonc/mdv387</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdv387</ArticleId><ArticleId IdType="pubmed">26386124</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KE, Deronic A, Hagerbrand K, et al. . Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion Biological Therapy. 2021;21(12):1635–1646. doi:10.1080/14712598.2021.1934446</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2021.1934446</ArticleId><ArticleId IdType="pubmed">34043482</ArticleId></ArticleIdList></Reference><Reference><Citation>Melero I, Castanon E, Alvarez M, et al. . Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18:558–576. doi:10.1038/s41571-021-00507-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-021-00507-y</ArticleId><ArticleId IdType="pmc">PMC8130796</ArticleId><ArticleId IdType="pubmed">34006998</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonderheide RH, Dutcher JP, Anderson JE, et al. . Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19:3280–3287. doi:10.1200/jco.2001.19.13.3280</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2001.19.13.3280</ArticleId><ArticleId IdType="pubmed">11432896</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hooren L, Vaccaro A, Ramachandran M, et al. . Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nat Commun. 2021;12:4127. doi:10.1038/s41467-021-24347-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24347-7</ArticleId><ArticleId IdType="pmc">PMC8257767</ArticleId><ArticleId IdType="pubmed">34226552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauss M, Donia M, Svane IM, et al. . B cells and tertiary lymphoid structures: friends or foes in cancer immunotherapy? Clin Cancer Res. 2022;28:1751–1758. doi:10.1158/1078-0432.CCR-21-1130</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-21-1130</ArticleId><ArticleId IdType="pmc">PMC9306440</ArticleId><ArticleId IdType="pubmed">34965949</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmink BA, Reddy SM, Gao J, et al. . B-cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–555. doi:10.1038/s41586-019-1922-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1922-8</ArticleId><ArticleId IdType="pmc">PMC8762581</ArticleId><ArticleId IdType="pubmed">31942075</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonia S, Goldberg SB, Balmanoukian A, et al. . Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299–308. doi:10.1016/S1470-2045(15)00544-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(15)00544-6</ArticleId><ArticleId IdType="pmc">PMC5500167</ArticleId><ArticleId IdType="pubmed">26858122</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonderheide RH. Abstract I12: CD40 immunotherapy for pancreatic cancer. Cancer Res. 2019;79:I12. doi:10.1158/1538-7445.Panca19-i12</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.Panca19-i12</ArticleId><ArticleId IdType="pmc">PMC3731141</ArticleId><ArticleId IdType="pubmed">23589109</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Hara M, O'Reilly E, Mick R, et al. . A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Cancer Res. 2019;79(Suppl. 13):CT004. doi:10.1158/1538-7445.SABCS18-CT004</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.SABCS18-CT004</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinicaltrials.gov . A study of CDX-1140 (CD40) as monotherapy or in combination in patients with advanced malignancies. 2020. https://clinicaltrials.gov/study/NCT03329950?term=CDX-1140&amp;rank=</Citation></Reference><Reference><Citation>Bajor DL, Gutierrez M, Vaccaro GM, et al. . Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2022;40(Suppl. 4):559. doi:10.1200/JCO.2022.40.4_suppl.559</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2022.40.4_suppl.559</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17:175–186. doi:10.1080/14737140.2017.1270208</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737140.2017.1270208</ArticleId><ArticleId IdType="pmc">PMC5533512</ArticleId><ArticleId IdType="pubmed">27927088</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton HM, Bernett MJ, Peipp M, et al. . Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood. 2010;116:3004–3012. doi:10.1182/blood-2010-01-265280</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-01-265280</ArticleId><ArticleId IdType="pubmed">20616215</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards DM, Sefrin JP, Gieffers C, et al. . Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother. 2020;16:377–387. doi:10.1080/21645515.2019.1653744</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1653744</ArticleId><ArticleId IdType="pmc">PMC7062441</ArticleId><ArticleId IdType="pubmed">31403344</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris EC, Neelapu SS, Giavridis T, et al. . Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85–96. doi:10.1038/s41577-021-00547-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00547-6</ArticleId><ArticleId IdType="pmc">PMC8127450</ArticleId><ArticleId IdType="pubmed">34002066</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>